Opus Genetics, Inc.
IRD
$2.05
$0.063.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.60% | -6.25% | -28.19% | -42.30% | -85.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.60% | -6.25% | -28.19% | -42.30% | -85.35% |
| Cost of Revenue | 14.65% | 63.38% | 76.63% | 51.12% | 42.96% |
| Gross Profit | 16.51% | -556.63% | -1,159.62% | -2,187.30% | -140.25% |
| SG&A Expenses | 72.30% | 67.38% | 38.95% | 52.28% | 31.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.86% | 65.87% | 60.34% | 52.19% | 34.56% |
| Operating Income | -26.13% | -144.53% | -198.97% | -222.58% | -201.37% |
| Income Before Tax | -150.80% | -313.50% | -419.27% | -476.82% | -193.52% |
| Income Tax Expenses | -- | -- | -- | -- | -100.61% |
| Earnings from Continuing Operations | -150.82% | -313.15% | -418.72% | -476.13% | -194.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.82% | -313.15% | -418.72% | -476.13% | -194.58% |
| EBIT | -26.13% | -144.53% | -198.97% | -222.58% | -201.37% |
| EBITDA | -26.02% | -144.44% | -198.98% | -222.70% | -201.33% |
| EPS Basic | -62.23% | -234.28% | -317.85% | -340.15% | -178.92% |
| Normalized Basic EPS | 22.61% | -63.63% | -124.33% | -141.61% | -177.79% |
| EPS Diluted | -62.23% | -228.62% | -309.84% | -331.48% | -182.29% |
| Normalized Diluted EPS | 22.61% | -60.30% | -119.16% | -135.88% | -181.44% |
| Average Basic Shares Outstanding | 99.28% | 62.22% | 29.25% | 23.76% | 18.22% |
| Average Diluted Shares Outstanding | 99.28% | 60.60% | 27.88% | 22.40% | 15.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |